You are here

Industry News

Advamed Smart Brief

June 19, 2018
The Turkish government on July 4 will launch a bidding process for a contract worth hundreds of millions of dollars for the p -More
June 19, 2018
A round of financing involving seven unnamed sources has brought in about $60.2 million for Carlsbad, Calif.-based Ra Medical -More
June 19, 2018
Braintree, Mass.-based Haemonetics has announced the completion of debt refinancing through which it secured a $700 million c -More
June 19, 2018
Texas Medical Center's TMCx 2018 Medical Device Accelerator Program has chosen VerteCore Technologies to become one of its pa -More
June 19, 2018
A Coherent Market Insights analysis predicts the worldwide cervical total disc replacement market will surpass $2.5 billion b -More
June 19, 2018
Sometimes working for your dad seems like destiny, but taking over the family business wasn't always the plan.  -More
June 19, 2018
Data from an ongoing feasibility study showed that at six months, use of Viveve Medical's cryogen-cooled, monopolar radiofreq -More
June 19, 2018
Microbot Medical has received word from the European Patent Office that it will grant the company a patent for its device des -More
June 19, 2018
The FDA has granted Johnson & Johnson Vision approval for its Idesign refractive studio, a technology designed to enable pers -More
June 19, 2018
Israeli firm DreaMed Diabetes' diabetes-management software Advisor Pro has been approved for marketing by the FDA.  -More

Industry News

PR Newswire
SAN ANTONIO, TX., May 23, 2018 - CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company's COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial results demonstrated 4.3% target lesion revascularization, 0.3% late stent thrombosis and 8.6% major adverse...
Helius Medical Technologies, Inc.
NEWTOWN, PA.,  April 11, 2018 - Helius Medical Technologies, Inc. (“Helius” or the “Company”) today announced the pricing of an underwritten public offering of 2,141,900 shares of its Class A common stock and warrants to purchase 2,141,900 shares of its Class A common stock at a public offering price of US$7.47 per share and accompanying warrant, before underwriting discounts and commissions.  The net proceeds to the Company from this offering, after deducting the underwriting discounts,...
PR Newswire
California-based Myoscience, Inc. announced today that it received 510k clearance from the US FDA for Smart Tip with Nerve Stim, the latest innovative tip for Myoscience’s iovera° platform technology. With the FDA clearance for Smart Tip with Nerve Stim, physicians will be able to stimulate a nerve in advance of delivering iovera° cold therapy to the treatment area, reducing patient treatment times. Additionally, the use of Smart Tip with Nerve Stim enables physicians using iovera° to access...
Media Planet
It sometimes strikes without warning. People of any age, race, ethnicity and gender are at risk. In fact, it is the leading killer of both men and women in America. It is heart disease, and each year it claims the lives of over 600,000 Americans, accounting for one-quarter of all deaths in the United States. 
Boston Scientific
Boston Scientific commends the efforts of key champions in the U.S. House and Senate for their successful efforts to suspend the medical device tax, allowing the device industry to reinvest in work to benefit patients.